cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 2063-2074

  Raynaud, Florence I ^a   Boxall, Frances E ^a   Goddard, Phyllis M ^a   Valenti, Melanie ^a   Jones, Mervyn ^a   Murrer, Barry A ^b   Abrams, Michael ^c   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; CARBOPLATIN; CIS AMMINEDICHLORO(2 METHYLPYRIDINE) PLATINUM(II); CISPLATIN; PLATINUM COMPLEX; SATRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG TRANSPORT; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PLASMACYTOMA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HALF-LIFE; HUMANS; KINETICS; LEUKEMIA L1210; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLASMACYTOMA; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030659405     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kelland, L. R. New platinum antitumor complexes. Crit. Rev. Oncol. Hematol., 15: 191-219, 1993.
2. Harrap, K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev., 12 (Suppl. A): 21-33, 1985.
3. Kelland, L. R., Murrer, B. A., Abel, G., Giandomenico, C. M., Mistry, P., and Harrap, K. R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res., 52: 822-828, 1992.
4. Kelland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., and Harrap, K. R. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res., 53: 2581-2586, 1993.
5. McKeage, M. J., Mistry, P., Ward, J., Boxall, F. E., Loh, S., O'Neill, C., Ellis, P., Kelland, L. R., Morgan, S. E., Murrer, B. A., Santabarbara, P., Harrap, K. R., and Judson, I. R. Phase I and pharmacological study of an oral platinum complex (JM216): dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol., 36: 451-458, 1995.
6. Kelland, L. R., Barnard, C. F. J., Mellish, K. J., Jones, M., Goddard, P. M., Valenti, M., Bryant, A., Murrer, B. A., and Harrap, K. R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res., 54: 5618-5622, 1994.
7. Kelland, L. R., Barnard, C. F. J., Evans, I. G., Murrer, B. A., Theobald, B. R. C., Vaughan, O. J., Wyer, S. B., Goddard, P. M., Jones, M., Valenti, M., Bryant, A., Rogers, P. M., and Harrap, K. R. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J. Med. Chem., 38: 3016-3024, 1995.
8. Goddard, P., Orr, R. M., Valenti, M. R., Barnard, C. F. J., Murrer, B. A., Kelland, L. R., and Harrap, K. R. Novel trans-platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and -resistant murine tumours. Anticancer Res., 16: 33-38, 1996.
9. Burchenal, J. H., Kalaher, K., Dew, K., and Lokys, L. Rationale for development of platinum analogs. Cancer Treat. Rep., 63: 1493-1498, 1979.
10. Goddard, P. M., Valenti, M. R., and Harrap, K. R. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Ann. Oncol., 2: 535-540, 1991.
11. Harrap, K. R., Jones, M., Siracky, J., Pollard, L. A., and Kelland, L. R. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol., 1: 65-76, 1990.
12. Schilder, R. J., LaCreta, F. P., Perez, R. P., Johnson, S. W., Brennan, J. M., Rogatko, A., Nash, S., McAleer, C., Hamilton, T. C., Roby, D., Young, R. C., Ozols, R. F., and O'Dwyer, P. J. Phase I and pharmacokinetic study of Ormaplatin (Tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res., 54: 709-717, 1994.
13. Levi, F. A., Zidani, R., Vannetzel, J-M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., Iacobelli, S., Adam, R., Kunstlinger, F., Gastiaburu, J., Bismuth, H., Jasmin, C., and Misset, J-L. Chronomodulated versus fixed infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst., 86: 1608-1617, 1994.
14. Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., Abad, A., Francois, E., Gamelin, E., Marty, M., Sastre, J., Seitz, J-F., and Ychou, M. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
15. Gietema, J. A., Veldhuis, G-J., Guchelaar, H-J., Willemse, P. H. B., Uges, D. R. A., Cats, A., Boonstra, H., van der Graaf, W. T. A., Sleijfer, D. T., de Vries, E. G. E., and Mulder, N. H. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br. J. Cancer., 71: 1302-1307, 1995.
16. Kavanagh, J. J., Edwards, C. L., Freedman, R. S., Finnegan, M. B., Balat, O., Tresukosol, D., Burk, K., Loechner, S., Hord, M., Franklin, J., and Kudelka, A. P. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol. Oncol., 58: 106-109, 1995.
17. Andrews, P. A. Mechanisms of acquired resistance to cisplatin. In: L. J. Goldstein and R. F. Ozols (eds.), Anticancer Drug Resistance: Advances in Molecular and Clinical Research, pp. 217-248. Kluwer Academic Publ., 1994.
18. Nishimura, T., Newkirk, K., Sessions, R. B., Andrews, P. A., Trock, B. J., Rasmussen, A. A., Montgomery, E. A., Bischoff, E. K., and Cullen, K. J. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin. Cancer Res., 2: 1859-1865, 1996.
19. Holford, J., Hartley, J., Murrer, B., and Kelland, L. In vitro evaluation of AMD473, a novel sterically hindered platinum(II) complex. Anal Oncol., 7 (Suppl. 1): 37, 1996.
20. Jones, M., Siracky, J., Kelland, L. R., and Harrap, K. R. Acquisition of platinum drug resistance and platinum cross-resistance patterns in a panel of human carcinoma xenografts. Br. J. Cancer, 67: 24-29, 1993.
21. Dalquist, A. Assay of intestinal disaccharidase. Anal. Biochem., 22: 99-107, 1968.
22. Jodrell, D. I., Newell, D. R., Morgan, S. E., Clinton, S. E., Bensted, J. P. M., Hugues, L. R., and Calvert, A. H. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br. J. Cancer, 64: 833-838, 1991.
23. McKeage, M. J., Boxall, F. E., Jones, M., and Harrap, K. R. Lack of neurotoxicity of oral bisacetatoaminedichlorocyclohexylamineplatinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res., 54: 629-631, 1994.
24. McKeage, M. J., Kelland, L. R., Boxall, F. E., Valenti, M. R., Jones, M., Goddard, P. M., Gwynne, J., and Harrap, K. R. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res., 54: 4118-4122, 1994.
25. Harstrick, A., Bokemeyer, C., Scharnofkse, M., Hapke, G., Reile, D., and Schmoll, H-J. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother. Pharmacol., 33: 43-47, 1993.
26. Van Der Vigh, W. F. J., and Klein, I. Protein binding of five platinum compounds: comparison of two ultrafiltration systems. Cancer Chemother. Pharmacol., 18: 129-132, 1986.
27. Raynaud, F. I., Boxall, F. E., Goddard, P., Barnard, C. F., Murrer, B. A., Kelland, L. R. Metabolism, Protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res., 16: 1857-1862, 1996.
28. Siddik, Z. H, Jones, M., Boxall, F. E., and Harrap, K. R., Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother. Pharmacol., 21: 19-24, 1988.
29. McKeage, M. J., Morgan, S. E., Boxall, F. E., Murrer, B. A., Hard, G. C., and Harrap, K. R. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/ amine platinum(IV) dicarboxylates. Cancer Chemother. Pharmacol., 33: 497-503, 1994.
30. Egorin, M. J., Van Eccho, D. A., Tipping, S. J., Olman, E. A., Whitacre, M. Y., Thompson, B. W., and Aisner, J. Pharmacokinetics and dosage reduction of cis-diammine (1-1, cyclobutane dicarboxylato) platinum in patients with normal and impaired renal function. Cancer Res., 44: 5432-5438, 1984.
31. McKeage, M. J., Morgan, S, E., Boxall, F. E., Murrer, B. A., Hard, G. C., and Harrap, K. R. Lack nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Br. J. Cancer., 67: 996-1000, 1993.